



November 7, 2019
Repertoire Genesis Inc.

Notice Regarding Collaboration Agreement with QIAGEN on Companion Diagnostics

Repertoire Genesis Inc. (Headquarters: Ibaraki, Osaka, hereinafter "Repertoire Genesis") entered into a world-wide, non-exclusive collaboration agreement with QIAGEN Manchester Limited. (Headquarters: Manchester, United Kingdom, hereinafter "QIAGEN") on companion diagnostics development and commercialization for cancer immunotherapy.

Cancer immunotherapy has been attracting worldwide attention in recent years, and is expected to show high efficacy on various cancers. However, some patients with cancer do not benefit from these therapies. Therefore, there is a need to develop companion diagnostics to confirm the patients who are likely to respond to these immunotherapies with favorable results.

In this collaboration agreement, we will harness the broad range of QIAGEN's products for life science field, companion diagnostics development, manufacturing and commercialization know-how, with cutting-edge Repertoire Genesis's T-Cell receptor repertoire analysis and bioinformatics technologies to accelerate companion diagnostics development and commercialization for cancer immunotherapy.

Repertoire Genesis will continue to promote further improvement and application of its unique immune diversity analysis technology including TCR/BCR repertoire analysis. In addition, by focusing on cutting-edge R&D and businesses necessary to protect world people's health, we will contribute to elucidating the mechanisms of diseases and accelerating the development of novel diagnostic and treatment methods.



About Repertoire Genesis

Repertoire Genesis Inc. is a Japanese biotechnology company dedicated to developing novel immune related treatment and diagnostics based on its corporate mission of “curing the incurable”. We take an approach to analyze the immune system in detail based on our unique immune diversity analysis technology such as TCR/BCR repertoire analysis and neoepitope analysis. Since our establishment in October 2014, we continue to challenge to provide effective treatments and diagnostics for unresolved medical problems specifically focusing on cancer, autoimmune and infectious diseases.

For further information, contact:

Administrative department, Repertoire Genesis Inc.

Tokyo Office: Nihonbashi Life Science Building 2 703,3-11-5 Nihonbashi honcho, Chuo-ku, Tokyo, 103-0023 Japan

Email: ir@repertoire.co.jp

URL: <https://www.repertoire.co.jp/en/>